Blog
RSS FeedPosted by Michael Wonder on 30 Aug 2022
Swissmedic authorises Moderna's Omicron targeting bivalent booster candidate MRNA-1273.214
29 August 2022 - Switzerland becomes among the first countries in the world to approve the use of a next-generation ...
Posted by Michael Wonder on 22 Aug 2022
New handbook on health economic assessments of medical devices
18 August 2022 - TLV carries out health economic assessments of medical technology products at the request of the Medical Technology ...
Posted by Michael Wonder on 04 Jul 2022
TLV reconsiders Orkambi's subsidy
4 July 2022 - TLV has started a reconsideration of the drug Orkambi in light of the fact that the ...
Posted by Michael Wonder on 27 Jun 2022
TLV receives assignments for medicines for rare diseases
27 June 2022 - The Government has commissioned the Swedish Dental and Pharmaceutical Benefits Agency (TLV) to analyse and make ...
Posted by Michael Wonder on 27 Jun 2022
TLV receives a new assignment on precision medicine and ATMP
27 June 2022 - The Government has commissioned the Swedish Dental and Pharmaceutical Benefits Agency (TLV) to continue the work ...
Posted by Michael Wonder on 20 Jun 2022
Zeposia is included in the high-cost protection with limitation
17 June 2022 - Zeposia (ozanimod) is included in the high-cost protection with limited subsidy from 17 June 2022. ...
Posted by Michael Wonder on 20 Jun 2022
Givlaari is included in the high-cost protection with limitation
17 June 2022 - Givlaari (givosiran) is included in the high-cost protection with limited subsidy to reduce attacks in patients with ...
Posted by Michael Wonder on 16 Jun 2022
Subsidy for medicine for Duchenne muscular dystrophy expires
16 June 2022 - The TLV has decided that Translarna, which is subsidised for patients with Duchenne muscular dystrophy, will not ...
Posted by Michael Wonder on 08 Jun 2022
TLV reconsiders subsidy of cyclin-dependent kinase 4/6 inhibitor Verzenios
8 June 2022 - Since April 2022, Verzenios has had market approval for the treatment of adult patients with early breast ...
Posted by Michael Wonder on 02 Jun 2022
TLV reconsiders subsidy of the IL-17 and IL-23 inhibitors
2 June 2022 - The TLV has started a trial for the interleukin 17 and interleukin 23 inhibitors. ...
Posted by Michael Wonder on 25 May 2022
Health economic assessment of Trodelvy in advanced triple negative breast cancer
23 May 2022 - TLV has produced a health economic assessment for the regions for the drug Trodelvy (sacituzumab govitecan). ...
Posted by Michael Wonder on 18 May 2022
TLV reconsiders subsidy of CGRP inhibitors
18 May 2022 - TLV has started a review of the CGRP inhibitors. ...
Posted by Michael Wonder on 17 May 2022
Health economic assessment of Xevudy for the treatment of COVID-19
17 May 2022 - TLV has produced a health economic assessment for the regions for the drug Xevudy (sotrovimab). ...
Posted by Michael Wonder on 16 May 2022
Tepmetko is granted a temporary subsidy
16 May 2022 - TLV has decided that Tepmetko (tepotinib) shall be included in the high-cost protection until the ordinary subsidy ...
Posted by Michael Wonder on 09 May 2022
Health economic assessment of Abecma in the treatment of multiple myeloma
6 May 2022 - TLV has produced a health economic assessment for the regions for Abecma (idecabtagene vicleucel). ...